Loading...

TRAW TRAWS PHARMA INC Expansion Plans 8-K Filing

TRWS

TRW

TRAWS PHARMA INC

(TRAW)

2026 8-K

Financial Results Announced

Earnings Report

Stock Offering Announcement

COVID-19 Treatment Update

COVID-19 Treatment Update

FDA Application Filed

Positive Interim Results

Management Changes

Annual Meeting Update

Earnings Announcement

Executive Stock Options

COVID Study Announcement

Management Changes

Asset Purchase Agreement

New Study Approval

Earnings Release

Product Expansion

Clinical Trials

Pre-Market Approval

Corporate Presentation

Financial Statements

Management Changes

Earnings Announcement

Management Changes

COVID-19 Treatment Data

Positive Study Results

Positive Study Results

Compliance Update

Capital Structure Update

Stockholder Meeting

Nasdaq Compliance

Management Changes

Phase 1 Completion

Securities Offering

Partnership Announcement

Partnership Announcement

Product Launch Plans

Earnings Report

Other Special Situation

Filing with Quantitative Data

Financial Results

Other Special Situation

Financial Update

Financial Update

Other Special Situation

Filing with Quantitative Data

Other Special Situation

Financial Update

Management Changes

Clinical Development Update

Clinical Development Update

External Links:

On February 19, 2026, Traws Pharma, Inc. announced the completion of its study on ratutrelvir, a treatment for mild-to-moderate COVID-19, and provided updates on tivoxavir marboxil for influenza prophylaxis. The company’s future results may vary due to various risks and uncertainties.

AI Assistant

TRAWS PHARMA INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.